Voloridge Investment Management LLC Sells 116,964 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Voloridge Investment Management LLC cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 85.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,497 shares of the specialty pharmaceutical company's stock after selling 116,964 shares during the period. Voloridge Investment Management LLC's holdings in Supernus Pharmaceuticals were worth $741,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Woodline Partners LP boosted its stake in Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock worth $15,326,000 after purchasing an additional 235,257 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Supernus Pharmaceuticals by 248.0% in the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock valued at $10,581,000 after buying an additional 208,552 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth about $6,847,000. Great Lakes Advisors LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth about $6,131,000. Finally, D. E. Shaw & Co. Inc. grew its holdings in Supernus Pharmaceuticals by 33.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock worth $19,731,000 after acquiring an additional 136,870 shares during the last quarter.

Supernus Pharmaceuticals Stock Up 0.3%

SUPN stock traded up $0.11 during midday trading on Friday, reaching $31.79. The stock had a trading volume of 750,724 shares, compared to its average volume of 482,619. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of 29.71 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The business has a fifty day simple moving average of $31.94 and a two-hundred day simple moving average of $34.60.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, May 16th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.